Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys

@article{Osborn2002PharmacokineticAP,
  title={Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-$\alpha$ Fusion Protein in Cynomolgus Monkeys},
  author={Blaire L. Osborn and Henrik S. Olsen and Bernardetta Nardelli and James H. Murray and Joe X. H. Zhou and Andrew Garcia and Gordon Moody and Liubov Zaritskaya and Cynthia Sung},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2002},
  volume={303},
  pages={540 - 548}
}
  • B. Osborn, H. Olsen, C. Sung
  • Published 1 November 2002
  • Biology, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
Interferon-α (IFN-α) is indicated for the treatment of certain viral infections including hepatitis B and C, and cancers such as melanoma. The short circulating half-life of unmodified IFN-α makes frequent dosing (daily or three times weekly) over an extended period (6–12 months or more) necessary. To improve the pharmacokinetics of IFN-α and decrease dosing frequency, IFN-α was fused to human serum albumin producing a new protein, Albuferon. In vitro comparisons of Albuferon and IFN-α showed… 

Figures and Tables from this paper

An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
  • C. Sung, B. Nardelli, P. Moore
  • Biology, Medicine
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2003
TLDR
In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.), Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression, suggesting a clinical opportunity for improved IFN-beta therapy.
A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy
TLDR
The results support further clinical studies of albumin-IFN-alpha for the treatment of patients with chronic hepatitis C and support dosing at 2- to 4-week intervals.
New and modified interferon alfas: Preclinical and clinical data
TLDR
This article describes ongoing preclinical and clinical studies of several new and modified IFN-α s, including one gene shuffled and one hybridized with human albumin, and a current phase I trial of a human recombinant IFN α -1.
Modulation of Interferon-Specific Gene Expression by Albumin-Interferon-α in Interferon-α-Experienced Patients with Chronic Hepatitis C
TLDR
Alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-alpha, and pretreatment levels of OAS1 and IFI44 correlated with hepatitis C virus RNA reduction at day 28.
Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV
TLDR
The potency and pharmacokinetic properties of the molecule are consistent with dosing at least twice daily with the potential for monthly dosing, and the biomarker and toxicological findings were consistent with a potent IFN molecule.
Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV
TLDR
The potency and pharmacokinetic properties of the molecule are consistent with dosing at least every two weeks with the potential for monthly dosing, and not 'at least twice daily' as presented in the original.
Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
TLDR
Releasable Albufusions (rAlbufusion) allows tailored design of the PK/PD profile and greatly extends the utility of conventional Albufusion technology.
Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C
TLDR
Albinterferon α-2b (alb-IFN), a recombinant polypeptide composed of IFN-α2b genetically fused to human albumin, has an extended half-life and early evidence indicates that it is efficacious and well tolerated.
...
...

References

SHOWING 1-10 OF 40 REFERENCES
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
  • R. Motzer, A. Rakhit, L. Hooftman
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
PEG-IFN is a modified form of IFNalpha2a with distinct pharmacokinetic advantages and immunomodulatory and antitumor activity for patients with advanced RCC and has potential for increased efficacy, less toxicity, or both.
Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys.
TLDR
The monkey appears to be a suitable pharmacokinetic model for the testing of rIFN-alpha A and could be useful in conjunction with a viral efficacy model.
Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery.
TLDR
Intramuscular injections produced lower peak concentrations and more sustained levels, but there was substantial variation in bioavailability (range 19-103%).
Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
TLDR
Peginterferon-alpha-2a (40 kD) is a valuable new treatment option and appears poised to play an important role in the first-line treatment of patients with chronic hepatitis C, including difficult-to-treat patients such as those with compensated cirrhosis and/or those infected with HCV genotype 1.
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
TLDR
The results show that PEG IFN-alpha-2b is easier to deliver, better tolerated, and perhaps more effective than IFn-alpha.
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.
TLDR
It is concluded that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.
Differences in Activity between α and β Type I Interferons Explored by Mutational Analysis*
TLDR
The structural basis for functional differences in α and β interferon subtypes is defined and a subset of these latter mutations did reduce activity in a manner analogous to IFN-α mutations.
Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin.
TLDR
The results provide a rationale for future testing of the biological effects of HLA, and support the initial hypothesis that gene fusion of hirudin to albumin would result in the expression of a slowly cleared hirUDin molecule, as well as retention of high-affinity inhibition of thrombin by the fusion protein.
The preclinical development of roferon®‐A
TLDR
Toxicological studies in ratsmice and several species of monkeys have failed to indicate the side effects that have been observed in humans, however studies in species in which interferon alfa‐2a is active and in others in which it is not have revealed similar pharmacokinetics and elimination mechanisms.
Cell and virus sensitivity studies with recombinant human alpha interferons.
TLDR
The cell sensitivity of recombinant human alpha interferons (rIFN-alpha) of greater than 95% purity (A,D and the hybrid A/D) and crude nature (B and F) was studied in human, bovine, mouse, and human cells and did not exhibit different antiviral spectra in vitro.
...
...